EANS-News: Epigenomics´ Epi proLung® BL Assay shows Strong Performance as Confirmation Test for Lung Cancer Diagnosis

--------------------------------------------------------------------------------
Corporate news transmitted by euro adhoc. The issuer/originator is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

New Products/Company Information/molecular diagnostics

Berlin, Germany, and Seattle, WA, U.S.A., February 14, 2012 (euro
adhoc) - Epigenomics AG (Frankfurt Prime Standard: ECX), the
German-American cancer molecular diagnostics company, is pleased to
announce the results from a clinical study conducted by Professor Dr.
Manfred Dietel and his team from the Institute of Pathology of the
Charité University Hospital in Berlin, Germany. In the reported
study, the clinical performance of the Epi proLung® BL assay (based
on Epigenomics´ proprietary biomarker detecting methylated SHOX2) was
evaluated in bronchial washings from patients suspected of having
lung carcinoma.

In the prospective study conducted between March 2011 and November
2011, a total of 228 bronchial washing specimens were submitted to
cytological analysis according to established clinical routine. In
addition, the Epi proLung® BL assay was performed on all patient
samples. Final clinical status indicated that 54 of the 228 subjects
were definitively diagnosed with lung carcinoma. Of the 54 confirmed
lung carcinoma subjects, 29 were detected by both tests, 12 were
detected by the Epi proLung® BL assay only, and 12 were detected by
cytological analysis only. The combination of both cytological
analysis and the Epi proLung® BL assay resulted in a final
sensitivity of 98% at a specificity of 92%. Only one confirmed lung
cancer case was missed with the combined analysis.

Based on these results, which independently confirm the clinical
utility of the Epi proLung® BL assay, Charité has announced that the
assay will be introduced into its clinical practice as a routine aid
in the diagnosis of lung cancer in patients with negative or
suspicious cytological results.

The results of this study will be presented by Prof. Dr. M. Dietel at
the Annual Meeting of the German Association of Pathologists end of
May in Berlin.

Dr. Uwe Staub, Senior Vice President of Development and Manufacturing
commented: "These results demonstrate the power of our proprietary
biomarker assay to further aid in a definitive diagnosis for lung
cancer. It is gratifying to see the implementation of this test into
a clinical routine practice, confirming our efforts in the
development of Epi proLung® BL assay".

- Ends -

Further Information

Contact Epigenomics AG

Antje Zeise
Manager IR | PR
Epigenomics AG
Tel +49 (0) 30 24345 368
ir@epigenomics.com
www.epigenomics.com

About Epigenomics

Epigenomics (www.epigenomics.com) is a molecular diagnostics company
developing and commercializing a pipeline of proprietary products for
cancer. The Company´s products enable doctors to diagnose cancer
earlier and more accurately, leading to improved outcomes for
patients. Epigenomics´ lead product, Epi proColon®, is a blood-based
test for the early detection of colorectal cancer, which is currently
marketed in Europe and is in development for the U.S.A. The Company´s
technology and products have been validated through multiple
partnerships with leading global diagnostic companies including
Abbott, QIAGEN, Sysmex, and Quest Diagnostics. Epigenomics is an
international company with operations in Europe and the U.S.A.

Epigenomics legal disclaimer

This communication expressly or implicitly contains certain
forward-looking statements concerning Epigenomics AG and its
business. Such statements involve certain known and unknown risks,
uncertainties and other factors which could cause the actual results,
financial condition, performance or achievements of Epigenomics AG to
be materially different from any future results, performance or
achievements expressed or implied by such forward-looking statements.
Epigenomics AG is providing this communication as of this date and
does not undertake to update any forward-looking statements contained
herein as a result of new information, future events or otherwise.

The information contained in this communication does not constitute
nor imply an offer to sell or transfer any product, and no product
based on this technology is currently available for sale by
Epigenomics in the United States or Canada. The analytical and
clinical performance characteristics of any Epigenomics product based
on this technology which may be sold at some future time in the U.S.
have not been established.

Further inquiry note:
Antje Zeise | CIRO
Manager IR/PR
Epigenomics AG
Tel: +49 30 24345 386
antje.zeise@epigenomics.com

end of announcement euro adhoc
--------------------------------------------------------------------------------

company: Epigenomics AG
Kleine Präsidentenstraße 1
D-10178 Berlin
phone: +49 30 24345-0
FAX: +49 30 24345-555
mail: ir@epigenomics.com
WWW: http://www.epigenomics.com
sector: Biotechnology
ISIN: DE000A1K0516
indexes: Prime All Share, Technology All Share
stockmarkets: free trade: Berlin, München, Hamburg, Düsseldorf, Stuttgart,
regulated dealing/prime standard: Frankfurt
language: English